GlassScriptPhysician profile
Erika A Strohmayer
NPI 1306018221
$4,135.69
in general payments reported to CMS, 2019-2025
34 companies · $410 in 2025
The $410 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,765 · 2020: $514 · 2021: $68.86 · 2022: $148 · 2023: $154 · 2024: $75.66 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599 · Education: $41.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.58 |
| Education | $41.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $735.01 | 2019-2025 | Jardiance |
| Amgen INC. | $527.97 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $459.23 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $302.49 | 2019-2020 | |
| Novo Nordisk INC | $276.61 | 2019-2025 | Ozempic |
| Corcept Therapeutics | $254.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $210.02 | 2019-2020 | |
| Insulet Corporation | $166.09 | 2019-2020 | |
| Aytu Biopharma, INC. | $113.16 | 2019-2020 | |
| Pfizer INC. | $96.81 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $96.10 | 2019-2020 | |
| Radius Health, INC. | $94.23 | 2019 | |
| Amarin Pharma, INC. | $83.09 | 2019-2020 | |
| Ibsa Pharma INC. | $82.00 | 2019 | |
| Merck Sharp & Dohme LLC | $67.24 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.98 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $45.00 | 2019 | |
| Dexcom, INC. | $44.93 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $42.85 | 2025 | Gvoke Hypopen, Recorlev |
| Eisai INC. | $41.84 | 2019 | |
| Cequr Corporation | $40.76 | 2025 | Cequr Simplicity |
| Vivus LLC | $35.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.41 | 2025 | |
| Esperion Therapeutics, INC. | $28.23 | 2025 | Nexletol |
| Mannkind Corporation | $27.21 | 2025 | |
| Madrigal Pharmaceuticals | $25.09 | 2025 | Rezdiffra |
| Medtronic Minimed, INC. | $22.91 | 2020 | |
| Endo Pharmaceuticals INC. | $22.16 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.00 | 2020 | |
| Sequel Med Tech, LLC | $18.67 | 2025 | Twiist |
| Currax Pharmaceuticals LLC | $18.17 | 2019 | |
| Shire North American Group INC | $16.29 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.40 | 2025 | Unithroid |
| Nalpropion Pharmaceuticals LLC | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Strohmayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.